Ipilimumab for recurrent glioblastoma (GBM).

e13026 Background: Currently available treatments for recurrent glioblastoma (GBM) are inadequate, and median survival is approximately 6 months. Ipilimumab (ipi) is an immune modulator that inhibits CTLA-4 and is active in refractory melanoma, including brain metastases. Methods: We retrospectively reviewed medical records of patients treated with ipi for recurrent GBM, and explored safety, response, and survival using Kaplan-Meier methodology. Results: There were 10 patients (6 men), median age 55 years (range, 41-65). All received prior radiotherapy and temozolomide, and 9 received prior bevacizumab. Ipi (3mg/kg/dose) was administered for 1st (1), 2nd (4), 3rd (4), or 6th(1) recurrence. Bevacizumab was administered concurrently to all patients to reduce corticosteroid requirements that can blunt ipi effect. Eight patents received concurrent GM-CSF. Other concurrent chemotherapy included nitrosoureas (5), carboplatin (1), temozolomide (1), or lapatinib (1). Corticosteroids (dexamethasone, 0.75 – 4.0 mg/...